Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
- 1 September 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (17) , 4271-4281
Abstract
Purpose: Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation. Inhibitors of BRAF and its substrates MEK1/2 are showing clinical promise in BRAFV600E PTC. PTC progression can be decades long, which is challenging in terms of toxicity and cost. We previously found that MEK1/2 require copper (Cu) for kinase activity and can be inhibited with the well-tolerated and economical Cu chelator tetrathiomolybdate (TM). We therefore tested TM for antineoplastic activity in BRAFV600E-positive PTC. Experimental Design: The efficacy of TM alone and in combination with current standard-of-care lenvatinib and sorafenib or BRAF and MEK1/2 inhibitors vemurafenib and trametinib was examined in BRAFV600E-positive human PTC cell lines and a genetically engineered mouse PTC model. Results: TM inhibited MEK1/2 kinase activity and transformed growth of PTC cells. TM was as or more potent than lenvatinib and sorafenib and enhanced the antineoplastic activity of sorafenib and vemurafenib. Activated ERK2, a substrate of MEK1/2, overcame this effect, consistent with TM deriving its antineoplastic activity by inhibiting MEK1/2. Oral TM reduced tumor burden and vemurafenib in a BrafV600E-positive mouse model of PTC. This effect was ascribed to a reduction of Cu in the tumors. TM reduced P-Erk1/2 in mouse PTC tumors, whereas genetic reduction of Cu in developing tumors trended towards a survival advantage. Finally, TM as a maintenance therapy after cessation of vemurafenib reduced tumor volume in the aforementioned PTC mouse model. Conclusions: TM inhibits BRAFV600E-driven PTC through inhibition of MEK1/2, supporting clinical evaluation of chronic TM therapy for this disease. Clin Cancer Res; 24(17); 4271–81. ©2018 AACR.Keywords
All Related Versions
This publication has 76 references indexed in Scilit:
- A Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase SignalingMolecular and Cellular Biology, 2012
- Thyroid cancer cell lines: an overviewFrontiers in Endocrinology, 2012
- A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2011
- Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approachesExpert Opinion on Investigational Drugs, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult MouseCancer Research, 2011
- Prognostic utility of BRAF mutation in papillary thyroid cancerMolecular and Cellular Endocrinology, 2010
- Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005Cancer Epidemiology, Biomarkers & Prevention, 2009
- Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and MisidentificationThe Journal of Clinical Endocrinology & Metabolism, 2008
- A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumorsGenes & Development, 2007